



# Bone Medical

ASX/MEDIA RELEASE

11 April 2005

## **BONE MEDICAL APPOINTS NON-EXECUTIVE DIRECTOR**

Bone Medical Limited (“Bone Medical”) (ASX: BNE) is pleased to announce the appointment of Mr R.Wayne Fritzsche as Non-Executive Director, effective immediately. Based in the United States, Mr Fritzsche has over 30 years experience in the biopharmaceutical industry.

Commencing his career in laboratory research, Mr Fritzsche progressed to executive positions in strategic planning and corporate development. He is currently CEO of Interim Medical Management, Chairman of Pressure Biosystems Inc. (formerly known as Boston Biomedica, Inc.), and serving on the Board of Directors for OrthoGenesis, Inc., and Perfused Organ Transport, Inc.

Bone Medical’s Chairman and Chief Executive Officer, Mr Michael Redman, said that, “We are delighted to welcome Wayne to the Board. I believe his experience and knowledge of the pharmaceutical industry will prove invaluable to the Company.”

“That someone with Wayne’s experience should wish to join Bone Medical is a validation of our positioning and potential,” said Mr Redman.

Most recently, Mr Fritzsche was President of Fritzsche and Associates, Inc., a technology and strategic consulting firm that specialises in assisting life science companies with technology assessment, corporate transactions, and capital formation.

He has served on many Boards and has been a founder of several firms within the pharmaceutical and biomedical industry including OrthoGenesis, Inc., Perfused Organ Transport, Inc., Cortex Pharmaceutical, PharmaFrontiers, Opexa Pharmaceuticals, Nobex, Inc., CardioCommand, and Clarion Pharmaceuticals.

In 1986 he was responsible for founding The Immune Response Company with Dr. Jonas Salk, of the Salk Institute. Mr Fritzsche has a degree in Chemistry from Rowan University and an MBA with the course work from a Master of Science in Accounting and Financial Management from University of San Diego.

ENDS-

For more information about Bone Medical Limited, please contact:

John Fitzgerald  
Chief Operating Officer  
+61 (0)419 600 375

Ann M. Nahajski  
Porter Novelli  
+61 8 9386 1233

Or visit: [www.bonemedical.com](http://www.bonemedical.com)

## **About Bone Medical Limited**

Bone Medical Limited is an international biopharmaceutical development company positioned to exploit the growing market in the treatment of bone disease particularly in osteoporosis and arthritis. Bone has a portfolio of biopharmaceutical development projects for the treatment of bone disease including,

### Osteoporosis

- *Capsitonin*<sup>TM</sup> oral calcitonin
- oral parathyroid hormone BN003
- combination therapy BN004
- bone cell regulators BN005/BN008

### Arthritis

- TNF regulators BN006
- joint protection & collagen tolerance BN007